Company Description
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom.
Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.
The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors.
In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease.
Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas.
It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV.
Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
| Country | United Kingdom |
| IPO Date | May 23, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 284 |
| CEO | Dr. Kevin Lee M.B.A., Ph.D. |
Contact Details
Address: Blocks A & B, Portway Building, Granta Park, Great Abington Cambridge, X0 CB21 6GS United Kingdom | |
| Phone | 011441223261503 |
| Website | bicycletherapeutics.com |
Stock Details
| Ticker Symbol | BCYC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $14.00 |
| CIK Code | 0001761612 |
| CUSIP Number | 088786108 |
| ISIN Number | US0887861088 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Kevin Lee M.B.A., Ph.D. | Chief Executive Officer and Executive Director |
| Lee H. Kalowski M.B.A. | President |
| Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE | Co-Founder and Non-Executive Director |
| Alistair Milnes | Chief Operating Officer |
| Dr. Michael Skynner B.sc. Ph.d., Ph.D. | Chief Technology Officer |
| Dr. Christian Heinis | Scientific Founder |
| Alethia Rene Young | Chief Financial Officer |
| Travis Thompson | Senior Vice President, Chief Accounting Officer and Principal Accounting Officer |
| Dr. Nicholas Keen Ph.D. | Chief Scientific Officer |
| Zafar Qadir | General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 18, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Apr 18, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 18, 2024 | 8-K | Current Report |
| Apr 15, 2024 | ARS | Filing |
| Apr 15, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 11, 2024 | 144 | Filing |
| Apr 3, 2024 | 144 | Filing |
| Apr 3, 2024 | 144 | Filing |
| Apr 3, 2024 | 144 | Filing |
| Apr 3, 2024 | 144 | Filing |